Frontier Pharma First-In-Class Innovation in Hematological Cancers First-in-Class Innovation in Hematological Cancers | страница 3

- Visualize the composition of the hematological cancers market in terms of dominant molecule
types and targets, highlighting what the current unmet needs are and how they can be addressed.
This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the hematological cancers pipeline and stratify by stage of development, molecule type
and molecular target. There are strong signs in the pipeline that the industry is seeking novel
approaches to treating hematological cancers.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class
products have been assessed and ranked according to clinical potential. Promising early-stage
targets have been reviewed in greater detail.
- Understand the level of versatility across the pipeline and within each molecular target. Assess
the pipeline activity of each versatile first-in-class product and the indications that they are being
developed for.
- Identify commercial opportunities in the hematological cancers deals landscape by analyzing
trends in licensing and co-development deals and producing a curated list of hematological cancer
therapies that have not yet been involved in deals, and may offer potential investment
opportunities.
Download sample Copy of This Report at:
http://www.radiantinsights.com/research/frontier-pharma--first-in-class-innovation-
in-hematological-cancers/request-sample
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Large Therapy Area with a High Degree of Pathophysiological Crossover 5
2.2 High Degree of First-in-Class Programs and Program Versatility in a Strong Pipeline 5
2.3 Sharp Increase in Deal Activity in Recent Years 5
3 The Case for Innovation in the Hematological Cancer Market 6
3.2 Diversification of Molecular Targets 7
Follow Us: